1. Evidence for a role of RUNX1 as recombinase cofactor for TCRβ rearrangements and pathological deletions in ETV6-RUNX1 ALL
- Author
-
A. Dröge, S. Schaper, Elizabeth Macintyre, Volkhard Seitz, N. Bedjaoui, Lora Dimitrova, Markus M. Heimesaat, Dido Lenze, Claudia D. Baldus, Maria Joosten, Erika Berg, Michael Hummel, C. Stocking, Anke Sommerfeld, U. Müller, Karsten Kleo, Sefer Elezkurtaj, S. Hennig, E. von der Wall, Christian Zinser, Agata Cieslak, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], HS Diagnomics GmbH [Berlin, Allemagne], Laboratoire d'Onco-Hematology [Paris], Institut Necker Enfants-Malades (INEM - UM 111 (UMR 8253 / U1151)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Heinrich Pette Institute [Hamburg], University Medical Center of Schleswig–Holstein = Universitätsklinikum Schleswig-Holstein (UKSH), Kiel University, Precigen Bioinformatics Germany GmbH [Munich, Allemagne], Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg] (UKE), The work was supported by Investitionsbank Berlin and the European Regional Development Fund (10155447 and 10155355 to the Charité and HS Diagnomics, respectively) and the Berlin Cancer Society (HUFF201629)., Bodescot, Myriam, and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)
- Subjects
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology ,0301 basic medicine ,Evolution ,Molecular biology ,Receptors, Antigen, T-Cell, alpha-beta ,T-Lymphocytes ,lcsh:Medicine ,Chromosomal translocation ,Thymus Gland ,Biology ,[SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology ,Article ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,hemic and lymphatic diseases ,Recombinase ,Animals ,T-cell receptor ,Lymphocyte Count ,Gene Rearrangement, beta-Chain T-Cell Antigen Receptor ,lcsh:Science ,Transcription factor ,Gene ,Cancer ,Mice, Knockout ,B-Lymphocytes ,Multidisciplinary ,Proto-Oncogene Proteins c-ets ,lcsh:R ,[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology ,[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology ,Gene rearrangement ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Repressor Proteins ,030104 developmental biology ,RUNX1 ,chemistry ,030220 oncology & carcinogenesis ,Core Binding Factor Alpha 2 Subunit ,embryonic structures ,lcsh:Q ,Chromatin immunoprecipitation ,Gene Deletion ,DNA - Abstract
T-cell receptor gene beta (TCRβ) gene rearrangement represents a complex, tightly regulated molecular mechanism involving excision, deletion and recombination of DNA during T-cell development. RUNX1, a well-known transcription factor for T-cell differentiation, has recently been described to act in addition as a recombinase cofactor for TCRδ gene rearrangements. In this work we employed a RUNX1 knock-out mouse model and demonstrate by deep TCRβ sequencing, immunostaining and chromatin immunoprecipitation that RUNX1 binds to the initiation site of TCRβ rearrangement and its homozygous inactivation induces severe structural changes of the rearranged TCRβ gene, whereas heterozygous inactivation has almost no impact. To compare the mouse model results to the situation in Acute Lymphoblastic Leukemia (ALL) we analyzed TCRβ gene rearrangements in T-ALL samples harboring heterozygous Runx1 mutations. Comparable to the Runx1+/− mouse model, heterozygous Runx1 mutations in T-ALL patients displayed no detectable impact on TCRβ rearrangements. Furthermore, we reanalyzed published sequence data from recurrent deletion borders of ALL patients carrying an ETV6-RUNX1 translocation. RUNX1 motifs were significantly overrepresented at the deletion ends arguing for a role of RUNX1 in the deletion mechanism. Collectively, our data imply a role of RUNX1 as recombinase cofactor for both physiological and aberrant deletions.
- Published
- 2020
- Full Text
- View/download PDF